

Clifford Leen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1648150/publications.pdf>

Version: 2024-02-01

70
papers

4,360
citations

147566

31
h-index

106150

65
g-index

70
all docs

70
docs citations

70
times ranked

5364
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 86, 248-257.	0.9	3
2	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639.	1.3	7
3	Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons. <i>Aids</i> , 2020, 34, 1485-1495.	1.0	3
4	Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation. <i>HIV Medicine</i> , 2020, 21, 309-321.	1.0	3
5	Epilepsia partialis continua complicated by disseminated tuberculosis and hemophagocytic lymphohistiocytosis: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 191.	0.4	4
6	Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 746-753.	1.3	7
7	The association between hepatocellular carcinoma and direct-acting antiviral treatment in patients with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 204-214.	1.9	20
8	British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019. <i>HIV Medicine</i> , 2019, 20, s2-s83.	1.0	8
9	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019, 393, 2428-2438.	6.3	627
10	A pilot experience of common European infectious diseases curriculum for medical students: the IDEAL summer school. <i>Future Microbiology</i> , 2019, 14, 369-372.	1.0	1
11	Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. <i>Aids</i> , 2018, 32, 1995-2004.	1.0	24
12	Chronic Kidney Disease Risk in African and Caribbean Populations With HIV. <i>Journal of Infectious Diseases</i> , 2018, 218, 1767-1772.	1.9	13
13	A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study. <i>Lancet HIV, the</i> , 2018, 5, e301-e308.	2.1	34
14	Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study. <i>Infection</i> , 2017, 45, 215-220.	2.3	8
15	Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. <i>Lancet HIV, the</i> , 2017, 4, e295-e302.	2.1	47
16	Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. <i>Clinical Infectious Diseases</i> , 2017, 64, 1413-1421.	2.9	66
17	Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. <i>Aids</i> , 2017, 31, 2525-2532.	1.0	66
18	British HIV Association guidelines for the treatment of HIV-positive adults with antiretroviral therapy 2015. <i>HIV Medicine</i> , 2016, 17, s2-s104.	1.0	78

#	ARTICLE	IF	CITATIONS
19	Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. <i>Journal of NeuroVirology</i> , 2016, 22, 852-860.	1.0	48
20	CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF. <i>Cytokine</i> , 2016, 83, 139-146.	1.4	22
21	Virological failure and development of new resistance mutations according to <scp>CD</scp>4 count at combination antiretroviral therapy initiation. <i>HIV Medicine</i> , 2016, 17, 368-372.	1.0	7
22	The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK. <i>PLoS ONE</i> , 2015, 10, e0132772.	1.1	2
23	Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1682-1685.e1.	1.5	11
24	Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected Persons. <i>Journal of Infectious Diseases</i> , 2014, 210, 234-243.	1.9	42
25	Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. <i>Aids</i> , 2014, 28, 1193-1202.	1.0	453
26	Laboratory adverse events and discontinuation of therapy according to CD4+ cell count at the start of antiretroviral therapy. <i>Aids</i> , 2014, 28, 1333-1339.	1.0	9
27	Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure. <i>Journal of Infectious Diseases</i> , 2014, 210, 363-373.	1.9	88
28	End-Stage Kidney Disease and Kidney Transplantation in HIV-Positive Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 177-180.	0.9	21
29	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). <i>HIV Medicine</i> , 2014, 15, 1-6.	1.0	101
30	Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. <i>Aids</i> , 2014, 28, 919-924.	1.0	9
31	Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1354-9.	1.3	30
32	British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. <i>HIV Medicine</i> , 2013, 14, 1-71.	1.0	43
33	Neurocognitive Function in HIV Infected Patients on Antiretroviral Therapy. <i>PLoS ONE</i> , 2013, 8, e61949.	1.1	58
34	Does Discordancy Between the CD4 Count and CD4 Percentage in HIV-Positive Individuals Influence Outcomes on Highly Active Antiretroviral Therapy?. <i>Journal of Infectious Diseases</i> , 2012, 205, 540-547.	1.9	5
35	HIV testing: getting the message across—a survey of knowledge, attitudes and practice among non-HIV specialist physicians. <i>Postgraduate Medical Journal</i> , 2012, 88, 59-65.	0.9	8
36	Biomarkers to Monitor Safety in People on ART and Risk of Mortality. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 51-58.	0.9	16

#	ARTICLE	IF	CITATIONS
37	Polymorphic lymphoid proliferations occurring in HIV-positive patients: report of a case responding to HAART. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 93-98.	1.4	8
38	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. <i>HIV Medicine</i> , 2012, 13, 1-6.	1.0	149
39	Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. <i>BMJ: British Medical Journal</i> , 2011, 343, d6016-d6016.	2.4	282
40	Hepatitis delta in HIV-infected individuals in Europe. <i>Aids</i> , 2011, 25, 1987-1992.	1.0	79
41	Outcomes in the First Year after Initiation of First-Line Haart among Heterosexual Men and Women in the Uk Chic Study. <i>Antiviral Therapy</i> , 2011, 16, 805-814.	0.6	36
42	HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. <i>European Journal of Neurology</i> , 2011, 18, 527-534.	1.7	85
43	Factors influencing lopinavir and atazanavir plasma concentration. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 129-137.	1.3	23
44	Data linkage reduces loss to follow-up in an observational HIV cohort study. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 1101-1109.	2.4	25
45	High Frequencies of Exposure to the Novel Human Parvovirus PARV4 in Hemophiliacs and Injection Drug Users, as Detected by a Serological Assay for PARV4 Antibodies. <i>Journal of Infectious Diseases</i> , 2009, 200, 1119-1125.	1.9	75
46	Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir. <i>Journal of Infectious Diseases</i> , 2009, 200, 710-714.	1.9	8
47	Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?. <i>Aids</i> , 2009, 23, 2507-2515.	1.0	38
48	Clinical epidemiology of HIV-associated end-stage renal failure in the UK. <i>Aids</i> , 2009, 23, 2517-2521.	1.0	48
49	CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. <i>Haematologica</i> , 2009, 94, 875-880.	1.7	81
50	Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 391-396.	0.9	4
51	British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy 2008. <i>HIV Medicine</i> , 2008, 9, 563-608.	1.0	530
52	Changes in Outcome of Persons Initiating Highly Active Antiretroviral Therapy at a CD4 Count Less Than 50 Cells/mm ³ . <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 202-205.	0.9	15
53	Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?. <i>Aids</i> , 2008, 22, 349-356.	1.0	18
54	Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. <i>Aids</i> , 2008, 22, 1943-1950.	1.0	16

#	ARTICLE	IF	CITATIONS
55	HIV-1-infected CD8+CD4+ T cells decay in vivo at a similar rate to infected CD4 T cells during HAART. <i>Aids</i> , 2008, 22, 57-65.	1.0	19
56	Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. <i>Antiviral Therapy</i> , 2008, 13, 675-85.	0.6	47
57	Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication. <i>Antiviral Therapy</i> , 2008, 13, 675-685.	0.6	90
58	Virus immunocapture provides evidence of CD8 lymphocyte-derived HIV-1 in vivo. <i>Aids</i> , 2007, 21, 1507-1513.	1.0	8
59	Acute dystonic reaction caused by metoclopramide, versus tetanus. <i>BMJ: British Medical Journal</i> , 2007, 334, 899-900.	2.4	19
60	Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. <i>Aids</i> , 2007, 21, 1717-1721.	1.0	75
61	Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. <i>Lancet, The</i> , 2007, 370, 1923-1928.	6.3	59
62	Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week Results. <i>Clinical Infectious Diseases</i> , 2007, 44, 1484-1492.	2.9	143
63	A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. <i>Aids</i> , 2006, 20, 2043-2050.	1.0	233
64	Pharmacokinetics of Enfuvirtide in a Patient with Impaired Renal Function. <i>Clinical Infectious Diseases</i> , 2004, 39, e119-e121.	2.9	13
65	High Levels of Human Immunodeficiency Virus Infection of CD8 Lymphocytes Expressing CD4 In Vivo. <i>Journal of Virology</i> , 2004, 78, 9862-9871.	1.5	38
66	Infection of CD8 Lymphocytes with HIV in vivo. <i>Clinical Science</i> , 2003, 104, 54P-54P.	0.0	0
67	Drug Resistance Genotypes Predict Response to Amprenavir-Containing Regimens in Highly Drug-Experienced HIV-1-Infected Patients. <i>Antiviral Therapy</i> , 2003, 8, 301-308.	0.6	0
68	HIV and Drug Misuse in the Edinburgh Cohort. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S35-S42.	0.9	78
69	Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use. <i>Aids</i> , 2000, 14, 1453-1454.	1.0	20
70	Features and Outcome of <i>Pneumocystis carinii</i> Pneumonia According to Risk Category for HIV Infection. <i>Scandinavian Journal of Infectious Diseases</i> , 1997, 29, 57-61.	1.5	6